India Pharma Outlook Team | Tuesday, 21 July 2026
Poviztra Approval has marked a major step for fatty liver treatment in India. Emcure Pharmaceuticals has received CDSCO approval to market Poviztra for eligible adults with MASH.
The approval expands treatment options for patients with a serious liver condition. Poviztra contains semaglutide, the same active ingredient used in Wegovy. The drug is meant for adults with non-cirrhotic MASH and moderate to advanced liver fibrosis.
The approval comes after the Central Drugs Standard Control Organisation cleared Wegovy for the same indication. It also strengthens Emcure's presence in India's growing metabolic disease market.
Poviztra is approved for adults diagnosed with non-cirrhotic MASH. Patients must also have moderate to advanced liver fibrosis.
MASH is a severe form of fatty liver disease. It causes fat buildup, inflammation, and scarring in the liver. Without treatment, the disease may progress to cirrhosis or liver failure.
Until recently, doctors mainly relied on lifestyle changes. Weight loss, healthy eating, and regular exercise remained the primary treatment methods.
The new approval gives specialists another medical option for eligible patients.
Also Read: Top 10 Performing Indian Pharma Stocks This Quarter (2026)
Poviztra is a co-marketed brand developed through Emcure's partnership with Novo Nordisk.
The two companies announced their collaboration in November 2025. The agreement aimed to introduce Poviztra as another brand of Wegovy in India.
According to Emcure, Novo Nordisk manufactures Poviztra at its European production facility. The product contains innovator recombinant DNA-origin semaglutide.
The approval also follows India's authorization of Wegovy for the same indication. That made it the first GLP-1 receptor agonist approved in the country for treating this form of MASH.
The expanded availability could improve access for patients requiring semaglutide-based treatment.
India is seeing a steady rise in obesity and metabolic disorders. These conditions increase the risk of developing MASH.
Many patients remain undiagnosed until the disease reaches an advanced stage. Early diagnosis and timely treatment can help slow disease progression.
Emcure Pharmaceuticals Ltd CEO & MD Satish Mehta said, "The approval for MASH marks an important milestone for patients living with a serious and often underdiagnosed liver disease."
The latest approval also reflects growing attention toward liver diseases linked to metabolic disorders. More treatment options could improve outcomes for eligible patients across India.
As awareness improves, physicians may identify more patients who can benefit from approved therapies alongside lifestyle changes.
